UFP (UFPT) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Document Information [Line Items]
Entity Central Index Key	0000914156
Entity Registrant Name	UFP TECHNOLOGIES INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-12648
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2314970
Entity Address, Address Line One	100 Hale Street
Entity Address, City or Town	Newburyport
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01950
City Area Code	978
Local Phone Number	352-2200
Title of 12(b) Security	Common Stock
Trading Symbol	UFPT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,578,605

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 9,937	$ 11,117
Receivables, net	61,477	39,384
Inventories	53,821	33,436
Prepaid expenses and other current assets	2,421	3,383
Refundable income taxes	2,590	0
Total current assets	133,842	87,320
Property, plant and equipment	107,809	126,837
Less accumulated depreciation and amortization	(51,463)	(70,268)
Net property, plant and equipment	56,346	56,569
Goodwill	112,657	107,905
Intangible assets, net	69,041	67,585
Non-qualified deferred compensation plan	3,882	4,327
Finance lease right of use assets	226	271
Operating lease right of use assets	12,114	9,053
Other assets	3,807	1,102
Total assets	391,915	334,132
Current liabilities:
Accounts payable	20,899	10,611
Accrued expenses	26,019	12,700
Deferred revenue	4,173	4,247
Finance lease liabilities	59	58
Operating lease liabilities	2,250	2,181
Income taxes payable	0	909
Current installments of long-term debt	4,000	4,000
Total current liabilities	60,996	34,706
Long-term debt, excluding current installments	67,000	71,000
Deferred income taxes	4,127	3,263
Non-qualified deferred compensation plan	3,886	4,337
Finance lease liabilities	171	215
Operating lease liabilities	10,029	6,903
Other liabilities	19,547	19,262
Total liabilities	165,756	139,686
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized; no shares issued	0	0
Common stock, $.01 par value, 20,000,000 shares authorized; 7,608,164 and 7,578,605 shares issued and outstanding, respectively, at September 30, 2022; 7,564,645 and 7,535,086 shares issued and outstanding, respectively, at December 31, 2021	76	75
Additional paid-in capital	35,396	34,151
Retained earnings	194,134	160,807
Accumulated other comprehensive loss	(2,860)	0
Treasury stock at cost: 29,559 shares at September 30, 2022 and December 31, 2021	(587)	(587)
Total stockholders’ equity	226,159	194,446
Total liabilities and stockholders' equity	$ 391,915	$ 334,132

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	7,608,164	7,564,645
Common stock, shares outstanding (in shares)	7,578,605	7,535,086
Treasury stock, shares (in shares)	29,559	29,559

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net sales	$ 96,970	$ 50,723	$ 262,555	$ 149,977
Cost of sales	71,447	38,707	195,575	111,938
Gross profit	25,523	12,016	66,980	38,039
Selling, general & administrative expenses	11,822	6,806	33,909	21,343
Acquisition costs	10	154	1,027	154
Change in fair value of contingent consideration	3,346	0	9,348	0
Gain on sale of Molded Fiber business	(15,623)		(15,623)
Loss (Gain) on sale of property, plant & equipment	3	(21)	(6,206)	(42)
Operating income	25,965	5,077	44,525	16,584
Interest income	(11)	0	(33)	(11)
Interest income	11	0	33	11
Interest expense	841	16	1,924	0
Other (income) expenses	(104)	4	(313)	(2)
Income before income tax expense	25,239	5,057	42,947	16,575
Income tax expense	5,699	1,268	9,620	3,908
Net income	$ 19,540	$ 3,789	$ 33,327	$ 12,667
Net income per share:
Basic (in dollars per share)	$ 2.58	$ 0.50	$ 4.41	$ 1.68
Diluted (in dollars per share)	$ 2.56	$ 0.50	$ 4.37	$ 1.67
Weighted average common shares outstanding:
Basic (in shares)	7,570	7,531	7,559	7,522
Diluted (in shares)	7,638	7,597	7,629	7,585
Comprehensive Income
Net income	$ 19,540	$ 3,789	$ 33,327	$ 12,667
Other comprehensive income:
Foreign currency translation adjustment	(1,725)	0	(2,860)	0
Other comprehensive loss	(1,725)	0	(2,860)	0
Comprehensive income	$ 17,815	$ 3,789	$ 30,467	$ 12,667

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020	7,500				30
Balance at Dec. 31, 2020	$ 75	$ 32,484	$ 144,921	$ 0	$ (587)	$ 176,893
Share-based compensation (in shares)	34				0
Share-based compensation	$ 0	501	0	0	$ 0	501
Net share settlement of RSUs (in shares)	(14)				0
Net share settlement of RSUs	$ 0	(738)	0	0	$ 0	(738)
Other comprehensive income	0	0	0	0	0	0
Net income	0	0	4,163		0	4,163
Other comprehensive income	$ 0	0	0	0	$ 0	0
Balance (in shares) at Mar. 31, 2021	7,520				30
Balance at Mar. 31, 2021	$ 75	32,247	149,084	0	$ (587)	180,819
Balance (in shares) at Dec. 31, 2020	7,500				30
Balance at Dec. 31, 2020	$ 75	32,484	144,921	0	$ (587)	176,893
Balance (in shares) at Jun. 30, 2021	7,531				30
Balance at Jun. 30, 2021	$ 75	33,027	153,799	0	$ (587)	186,314
Balance (in shares) at Dec. 31, 2020	7,500				30
Balance at Dec. 31, 2020	$ 75	32,484	144,921	0	$ (587)	176,893
Other comprehensive income						0
Net income						12,667
Other comprehensive income						0
Balance (in shares) at Sep. 30, 2021	7,531				30
Balance at Sep. 30, 2021	$ 75	33,677	157,588	0	$ (587)	190,753
Balance (in shares) at Mar. 31, 2021	7,520				30
Balance at Mar. 31, 2021	$ 75	32,247	149,084	0	$ (587)	180,819
Share-based compensation (in shares)	4				0
Share-based compensation	$ 0	620	0	0	$ 0	620
Net share settlement of RSUs	0	(2)	0	0	0	(2)
Other comprehensive income	0	0	0	0	0	0
Net income	$ 0	0	4,715	0	$ 0	4,715
Exercise of stock options (in shares)	7				0
Exercise of stock options	$ 0	162	0	0	$ 0	162
Other comprehensive income	$ 0	0	0	0	$ 0	0
Balance (in shares) at Jun. 30, 2021	7,531				30
Balance at Jun. 30, 2021	$ 75	33,027	153,799	0	$ (587)	186,314
Share-based compensation (in shares)	0
Share-based compensation	$ 0	650	0	0		650
Net share settlement of RSUs	0	0	0	0		0
Other comprehensive income	0	0	0	0		0
Net income	$ 0	0	3,789	0		3,789
Exercise of stock options (in shares)	0
Exercise of stock options	$ 0	0	0	0		0
Other comprehensive income	$ 0	0	0	0		0
Balance (in shares) at Sep. 30, 2021	7,531				30
Balance at Sep. 30, 2021	$ 75	33,677	157,588	0	$ (587)	190,753
Balance (in shares) at Dec. 31, 2021	7,535				30
Balance at Dec. 31, 2021	$ 75	34,151	160,807	0	$ (587)	194,446
Share-based compensation (in shares)	46				0
Share-based compensation	$ 1	691	0	0	$ 0	692
Net share settlement of RSUs (in shares)	(20)				0
Net share settlement of RSUs	$ 0	(1,299)	0	0	$ 0	(1,299)
Other comprehensive income	0	0	0	381	0	381
Net income	0	0	4,858		0	4,858
Other comprehensive income	$ 0	0	0	381	$ 0	381
Balance (in shares) at Mar. 31, 2022	7,561				30
Balance at Mar. 31, 2022	$ 76	33,543	165,665	381	$ (587)	199,078
Balance (in shares) at Dec. 31, 2021	7,535				30
Balance at Dec. 31, 2021	$ 75	34,151	160,807	0	$ (587)	194,446
Other comprehensive income						(2,860)
Net income						33,327
Other comprehensive income						(2,860)
Balance (in shares) at Sep. 30, 2022	7,569				30
Balance at Sep. 30, 2022	$ 76	35,396	194,134	(2,860)	$ (587)	226,159
Balance (in shares) at Mar. 31, 2022	7,561				30
Balance at Mar. 31, 2022	$ 76	33,543	165,665	381	$ (587)	199,078
Share-based compensation (in shares)	4				0
Share-based compensation	$ 0	781	0	0	$ 0	781
Net share settlement of RSUs	0	(3)	0	0	0	(3)
Other comprehensive income	0	0	0	(1,516)	0	(1,516)
Net income	$ 0	0	8,929	0	$ 0	8,929
Exercise of stock options (in shares)	1				0
Exercise of stock options	$ 0	21	0	0	$ 0	21
Other comprehensive income	$ 0	0	0	(1,516)	$ 0	(1,516)
Balance (in shares) at Jun. 30, 2022	7,566				30
Balance at Jun. 30, 2022	$ 76	34,342	174,594	(1,135)	$ (587)	207,290
Share-based compensation (in shares)	0				0
Share-based compensation	$ 0	897	0	0	$ 0	897
Net share settlement of RSUs	0	(189)	0	0	0	(189)
Other comprehensive income	0	0	0	(1,725)	0	(1,725)
Net income	$ 0	0	19,540	0	$ 0	19,540
Exercise of stock options (in shares)	14				0
Exercise of stock options	$ 0	346	0	0	$ 0	346
Other comprehensive income	$ 0	0	0	(1,725)	$ 0	(1,725)
Balance (in shares) at Sep. 30, 2022	7,569				30
Balance at Sep. 30, 2022	$ 76	$ 35,396	$ 194,134	$ (2,860)	$ (587)	$ 226,159

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands, € in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Cash flows from operating activities:
Net income	$ 33,327	$ 12,667
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	9,137	6,209
Gain on disposal of property, plant & equipment	(6,206)	(43)
Gain on sale of Molded Fiber business	(15,623)	0
Share-based compensation	2,370	1,771
Interest expense on finance leases	4	2
Deferred income taxes	415	482
Change in fair value of contingent consideration	9,348	0
Changes in operating assets and liabilities:
Receivables, net	(19,841)	(6,028)
Inventories	(20,085)	(3,032)
Prepaid expenses and other current assets	118	(517)
Refundable income taxes	(3,624)	(848)
Other assets	(2,637)	72
Accounts payable	6,334	3,210
Accrued expenses	12,987	417
Deferred revenue	501	(216)
Non-qualified deferred compensation plan and other liabilities	(6,669)	(469)
Net cash provided by operating activities	(144)	13,677
Cash flows from investing activities:
Additions to property, plant, and equipment	(10,816)	(4,277)
Proceeds from sale of Molded Fiber	29,007	0
Proceeds from sale of fixed assets	6,717	51
Net cash provided by (used in) investing activities	4,255	(4,226)
Cash flows from financing activities:
Proceeds from advances on revolving line of credit	44,000	0
Payments on revolving line of credit	(45,000)	0
Principal payments of long-term debt	(3,000)	0
Principal payments on finance lease obligations	(47)	(13)
Proceeds from exercise of stock options	367	162
Payment of statutory withholdings for restricted stock units vested	(1,491)	(740)
Net cash used in financing activities	(5,171)	(591)
Effect of foreign currency exchange rates on cash and cash equivalents	(120)	0
Net (decrease) increase in cash and cash equivalents	(1,180)	8,860
Cash and cash equivalents at beginning of period	11,117	24,234
Cash and cash equivalents at end of period	9,937	33,094
Advant Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired	(20,768)	0
DAS Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired	$ 115	$ 0

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	( 1 Basis of Presentation The interim condensed consolidated financial statements of UFP Technologies, Inc. (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10 not December 31, 2021, 2021 10 The condensed consolidated balance sheets as of September 30, 2022 December 31, 2021, three nine September 30, 2022 2021, three nine September 30, 2022 2021, nine September 30, 2022 2021 December 31, 2021 not The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three nine September 30, 2022 not December 31, 2022. New Accounting Policy The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not not Recent Accounting Pronouncements There are no

Note 2 - Acquisitions and Dives

Note 2 - Acquisitions and Divestiture	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	( 2 Acquisitions and Divestiture Molded Fiber On July 26, 2022, three nine September 30, 2022. December 31, 2021. Advant Medical On March 16, 2022, €19.0 Founded in 1993, The following table summarizes the allocation of consideration paid to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Fair value of considerations transferred Cash paid at closing $ 23,608 Other liability 395 Cash from Advant (2,840 ) Total consideration $ 21,163 Purchase price allocation Accounts receivable $ 2,299 Inventory 2,410 Other current assets 213 Property, plant, and equipment 5,704 Customer contracts & relationships 2,925 Intellectual property 2,127 Non-compete agreement 259 Lease right of use assets 289 Other assets 41 Goodwill 7,140 Total identifiable assets $ 23,407 Accounts payable (772 ) Accrued expenses (668 ) Income taxes (66 ) Deferred taxes (449 ) Lease liabilities (289 ) Net assets acquired $ 21,163 Acquisition costs associated with the transaction were approximately $789 thousand, of which $759 thousand was charged to expense in the nine September 30, 2022, December 31, 2021. The amount of revenue and earnings of Advant recognized since the acquisition date, which is included in the condensed consolidated statement of income for the nine September 30, 2022, Pro-forma statements The following table contains an unaudited pro forma condensed consolidated statement of operations for the nine September 30, 2022 2021 three September 30, 2021, Three Months Ended September 30, Nine Months Ended September 30, 2021 2022 2021 (Unaudited) (Unaudited) (Unaudited) Sales $ 56,194 $ 266,782 $ 166,273 Operating Income $ 5,440 $ 45,268 $ 18,187 Net Income $ 4,018 $ 33,881 $ 13,796 Earnings per share: Basic $ 0.53 $ 4.48 $ 1.83 Diluted $ 0.53 $ 4.44 $ 1.82 The above unaudited pro forma information is presented for illustrative purposes only and may not may DAS Medical On December 22, 2021 may four In connection with its entry into the Purchase Agreement, the Company also entered into an Agreement for the Purchase and Sale of Personal Goodwill (the “Goodwill Agreement”) with the purchase price beneficiaries. Pursuant to the terms of the Goodwill Agreement, on December 22, 2021, The Company has also entered into Non-Competition Agreements with the beneficiaries and the Company has agreed to pay additional consideration to the parties to the Non-Competition Agreements, including an aggregate of $10.0 million in payments over the ten Founded in 2010, The following table summarizes the allocation of consideration paid to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Fair value of considerations transferred Cash paid at closing $ 95,000 Contingent liability (Earn-out) 5,188 Non-compete agreements 8,855 Cash from DAS (8,316 ) Working capital adjustment (115 ) Total consideration $ 100,612 Purchase price allocation Accounts receivable $ 2,351 Inventory 7,570 Other current assets 68 Property, plant, and equipment 3,314 Customer contracts & relationships 36,730 Intellectual property 2,380 Non-compete agreement 4,697 Lease right of use assets 1,221 Goodwill 51,985 Total identifiable assets $ 110,316 Accounts payable (5,238 ) Accrued expenses (3,238 ) Deferred revenue (7 ) Lease liabilities (1,221 ) Net assets acquired $ 100,612 Acquisition costs associated with the transaction were approximately $448 thousand, of which $155 thousand were charged to expense in the nine September 30, 2022, December 31, 2021. Contech Medical On October 12, 2021, 12 June 30, 2022. Founded in 1987, five one five The following table summarizes the allocation of consideration paid to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s estimates of fair value (in thousands): Fair value of considerations transferred Cash paid at closing $ 9,766 Contingent liability (Earn-out) 4,543 Other liability 500 Cash from Contech (266 ) Total consideration $ 14,543 Purchase price allocation Accounts receivable $ 2,851 Inventory 2,320 Other current assets 37 Property, plant, and equipment 1,170 Customer contracts & relationships 3,043 Intellectual property 2,247 Non-compete agreement 86 Lease right of use assets 1,523 Goodwill 4,278 Total identifiable assets $ 17,555 Accounts payable (1,015 ) Accrued expenses (414 ) Deferred revenue (60 ) Lease liabilities (1,523 ) Net assets acquired $ 14,543 Acquisition costs associated with the transaction were approximately $153 thousand, of which $113 thousand were charged to expense in the nine September 30, 2022, December 31, 2021. Pro-forma statements The following table contains an unaudited pro forma condensed consolidated statement of operations for the three six September 30, 2021, Three-month Period Ended September 30, 2021 Nine-month Period Ended September 30, 2021 (Unaudited) (Unaudited) Sales $ 69,055 $ 201,660 Operating income $ 7,627 $ 23,030 Net income $ 5,707 $ 18,526 Earnings per share: Basic $ 0.76 $ 2.46 Diluted $ 0.75 $ 2.44 The above unaudited pro forma information is presented for illustrative purposes only and may not may

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	( 3 Revenue Recognition The Company recognizes revenue when a customer obtains control of a promised good or service. The amount of revenue recognized reflects the consideration that the Company expects to be entitled to in exchange for promised goods or services. The Company recognizes revenue in accordance with the core principles of ASC 606 1 2 3 4 5 not not Disaggregated Revenue The following table presents the Company’s revenue disaggregated by the major types of goods and services sold to the Company’s customers (in thousands): Three Months Ended Nine Months Ended September 30, September 30, Net sales of: 2022 2021 2022 2021 Products $ 92,860 $ 49,613 $ 251,996 $ 146,402 Tooling and Machinery 2,659 405 5,984 1,149 Engineering services 1,451 705 4,575 2,426 Total net sales $ 96,970 $ 50,723 $ 262,555 $ 149,977 Contract balances Timing of revenue recognition may The following table presents a roll-forward of contract liabilities activity for the nine September 30, 2022 2021 Contract Liabilities Nine Months Ended September 30, 2022 2021 Deferred revenue - beginning of period $ 4,247 $ 1,887 Increases due to consideration received from customers 4,836 2,111 Revenue recognized (4,335 ) (1,192 ) Decrease due to sale of Molded Fiber (575 ) - Deferred revenue - end of period $ 4,173 $ 2,806 Revenue recognized during the nine September 30, 2022 2021 When invoicing occurs after revenue recognition, the Company has contract assets, included within “receivables” on the condensed consolidated balance sheet. Contract Assets Nine Months Ended September 30, 2022 2021 Unbilled receivables - beginning of period $ 74 $ 271 Increases due to revenue recognized, not invoiced to customers 3,065 1,461 Decreases due to customer invoicing (2,429 ) (1,509 ) Unbilled receivables - end of period $ 710 $ 223 The following table presents a roll-forward of contract assets activity for the nine September 30, 2022 2021

Note 4 - Supplemental Cash Flow

Note 4 - Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	( 4 Supplemental Cash Flow Information Nine Months Ended September 30, 2022 2021 (in thousands) Cash paid for: Interest $ 1,869 $ 39 Income taxes, net of refunds 12,315 4,274 Non-cash investing and financing activities: Capital additions accrued but not yet paid $ 133 $ 225

Note 5 - Receivables and Allowa

Note 5 - Receivables and Allowance for Credit Losses	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	( 5 Receivables and Allowance for Credit Losses Receivables consist of the following (in thousands): September 30, December 31, 2022 2021 Accounts receivable–trade $ 65,814 $ 39,903 Less allowance for credit losses (741 ) (519 ) Receivables, net $ 65,073 $ 39,384 The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' trade accounts receivables. Due to the short-term nature of such receivables, the estimate of the amount of accounts receivable that may not The following table provides a roll-forward of the allowance for credit losses that is deducted from accounts receivable to present the net amount expected to be collected as of September 30, 2022 2021 Allowance for Credit Losses Nine Months Ended September 30, 2022 2021 Allowance - beginning of period $ 519 $ 484 Provision for expected credit losses 275 92 Amounts written off against the allowance (53 ) (54 ) Allowance - end of period $ 741 $ 522

Note 6 - Fair Value of Financia

Note 6 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	( 6 Fair Value of Financial Instruments Financial instruments recorded at fair value in the consolidated balance sheets, or disclosed at fair value in the footnotes, are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels defined by ASC 820, Fair Value Measurements and Disclosures Level 1 Valued based on unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Valued based on either directly or indirectly observable prices for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 Valued based on management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. The following table presents the fair value and hierarchy levels, for financial assets that are measured at fair value on a recurring basis (in thousands): September 30, 2022 December 31, 2021 Level 2 Assets (Liabilities): Derivative financial instruments $ 26 $ (176 ) Level 3 Purchase price contingent consideration (Note 2): Accrued contingent consideration (earn-out) $ (19,079 ) $ (9,731 ) Present value of non-competition payments (9,746 ) (8,855 ) Derivative financial instruments consist of an interest rate swap for which fair value is determined through the use of a pricing model that utilizes verifiable inputs such as market interest rates that are observable at commonly quoted intervals for the full term of the swap agreement. In connection with the acquisitions discussed in Note 2, 3 September 30, 2022 September 30, 2022 three nine September 30, 2022, In connection with the DAS Medical acquisition, the Company has entered into Non-Competition Agreements with the beneficiaries and the Company has agreed to pay additional consideration to the parties to the Non-Competition Agreements, including an aggregate of $10.0 million in payments over the ten €375 three five The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, that are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.

Note 7 - Share-based Compensati

Note 7 - Share-based Compensation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	( 7 Share-Based Compensation Share-based compensation is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). The Company issues share-based awards through several plans that are described in detail in the notes to the consolidated financial statements for the year ended December 31, 2021. Three Months Ended Nine Months Ended September 30, September 30, Share-based compensation related to: 2022 2021 2022 2021 Common stock grants $ 100 $ 100 $ 300 $ 300 Stock option grants 75 52 188 157 Restricted Stock Unit Awards ("RSUs") 722 498 1,882 1,314 Total share-based compensation $ 897 $ 650 $ 2,370 $ 1,771 The total income tax benefit recognized in the condensed consolidated statements of income for share-based compensa‐tion arrangements was approximately $485 thousand and $167 thousand for the three September 30, 2022 2021, nine September 30, 2022 2021, Common stock grants The compensation expense for common stock grants during the nine September 30, 2022, Stock Option grants The following is a summary of stock option activity under all plans for the nine September 30, 2022: Shares Under Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2021 98,671 $ 33.53 Granted 9,876 77.28 Exercised (15,245 ) 24.10 Outstanding at September 30, 2022 93,302 $ 39.70 6.13 $ 4,305 Exercisable at September 30, 2022 83,426 $ 35.26 5.71 $ 4,220 Vested and expected to vest at September 30, 2022 93,302 $ 39.70 $ 6.13 $ 4,305 On June 8, 2022, Expected volatility 34.7 % Expected dividends None Risk-free interest rate 2.9 % Exercise price $ 77.28 Expected term (years) 6.2 Weighted-average grant date fair value $ 30.37 The stock volatility for each grant is determined based on a review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term, and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods correspond‐ing with the expected term of the option. The expected term is estimated based on historical option exercise activity. During the nine September 30, 2022 2021, nine September 30, 2022, Zero 2021. Restricted Stock Unit awards The following table summarizes information about RSU activity during the nine September 30, 2022: Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 101,168 $ 41.78 Awarded 51,981 74.94 Shares vested (49,575 ) 41.05 Shares forfeited (947 ) 64.32 Outstanding at September 30, 2022 102,627 $ 55.29 At the Company’s discretion, upon vesting, RSU holders are given the option to net-share settle to cover the required minimum withholding tax and the remaining amount is converted into the equivalent number of common shares and issued to the RSU holder. During the nine September 30, 2022 2021, As of September 30, 2022,

Note 8 - Inventories

Note 8 - Inventories	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	( 8 Inventories Inventories are stated at the lower of cost (determined using the first first September 30, December 31, 2022 2021 Raw materials $ 39,071 $ 22,184 Work in process 5,981 4,205 Finished goods 8,769 7,047 Total inventory $ 53,821 $ 33,436

Note 9 - Leases

Note 9 - Leases	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	( 9 Leases The Company has operating and finance leases for offices, manufacturing plants, vehicles and certain office and manufacturing equipment. Leases with an initial term of 12 not not ROU assets represent the Company's right to use an underlying asset during the lease term and lease liabilities represent the Company's obligation to make lease payments pursuant to the lease. ROU assets and lease liabilities are recognized at commencement date based on the net present value of fixed lease payments over the lease term. The Company's assumed lease term includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets are also adjusted for any deferred or accrued rent. As the Company's leases do not Nine Months Ended September 30, ($ in thousands) 2022 2021 Lease Cost: Finance lease cost: Amortization of right of use assets $ 45 $ 12 Interest on lease liabilities 4 2 Operating lease cost 1,962 896 Variable lease cost 228 169 Short-term lease cost 49 30 Total lease cost $ 2,288 $ 1,109 Nine Months Ended September 30, ($ in thousands) 2022 2021 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 1,839 $ 909 Financing cash flows from finance leases 47 11 Weighted-average remaining lease term (years): Finance 3.79 5.58 Operating 3.88 1.39 Weighted-average discount rate: Finance 2.10 % 2.26 % Operating 2.75 % 3.95 % The aggregate future lease payments for leases as of September 30, 2022 Finance Operating Remainder of 2022 $ 16 $ 611 2023 63 2,211 2024 63 2,190 2025 63 1,957 2026 28 1,733 Thereafter 6 4,775 Total lease payments 239 13,477 Less: Interest (9 ) (1,198 ) Present value of lease liabilities $ 230 $ 12,279

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	( 10 Net Income Per Share Basic income per share is based on the weighted average number of shares of common stock outstanding. Diluted income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalent shares outstanding during each period. The weighted average number of shares used to compute basic and diluted net income per share consisted of the following (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic weighted average common shares outstanding 7,570 7,531 7,559 7,522 Weighted average common equivalent shares due to restricted stock, stock options and RSUs 68 66 70 63 Diluted weighted average common shares outstanding 7,638 7,597 7,629 7,585 The computation of diluted net income per share excludes the effect of the potential exercise of stock awards, including stock options, when the average market price of the common stock is lower than the exercise price of the related stock options during the period. These outstanding stock options are not three nine September 30, 2022, three nine September 30, 2021,

Note 11 - Segment Reporting

Note 11 - Segment Reporting	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	( 11 Segment Reporting The Company consists of a single operating and reportable segment. One customer comprised 25.1% and 20.5% of the Company’s consolidated revenues for the three nine September 30, 2022, No 10% 2021. September 30, 2022, one December 31, 2021, no 10% The Company’s products are primarily sold to customers within the Medical, Automotive, Aerospace & Defense, Consumer, Industrial, and Electronics markets. Net sales by market for the three nine September 30, 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021(1) 2022 2021(1) Market Net Sales % Net Sales % Net Sales % Net Sales % Medical $ 81,591 84.1 % $ 32,376 63.8 % $ 208,464 79.4 % $ 95,088 63.4 % Automotive 4,681 4.8 % 3,852 7.6 % 13,383 5.1 % 12,065 8.0 % Aerospace & Defense 3,590 3.7 % 3,881 7.7 % 11,097 4.2 % 12,636 8.4 % Consumer 3,099 3.2 % 6,449 12.7 % 15,644 6.0 % 18,125 12.1 % Industrial 2,748 2.8 % 2,162 4.3 % 7,924 2.9 % 6,508 4.2 % Electronics 1,261 1.3 % 2,003 4.0 % 6,043 2.4 % 5,555 3.7 % Net Sales $ 96,970 100.0 % $ 50,723 100.0 % $ 262,555 100.0 % $ 149,977 100.0 % ( 1 Certain amounts for the three nine September 30, 2021,

Note 12 - Goodwill and Other In

Note 12 - Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	( 12 Goodwill and Other Intangible Assets The changes in the carrying amount of goodwill for the nine September 30, 2022 Goodwill December 31, 2021 $ 107,905 Acquired in Advant Medical business combination (See Note 2) 7,140 DAS working capital adjustment 196 Sale of Molded Fiber (1,778 ) Foreign currency translation (806 ) September 30, 2022 $ 112,657 The carrying values of the Company’s definite lived intangible assets as of September 30, 2022 Intellectual Property / Tradename & Brand Non- Compete Customer List Total Weighted-average amortization period (years) 11.9 9.3 20 Gross amount $ 6,881 $ 5,474 $ 64,922 $ 77,277 Accumulated amortization (570 ) (822 ) (6,844 ) (8,236 ) Net balance $ 6,311 $ 4,652 $ 58,078 $ 69,041 Amortization expense related to intangible assets was approximately $1.1 million and $314 thousand, respectively, for the three September 30, 2022 2021, nine September 30, 2022 2021. September 30, 2022 Remainder of 2022 $ 1,123 2023 4,409 2024 4,401 2025 4,401 2026 4,398 Thereafter 50,309 Total $ 69,041

Note 13 - Other Long-term Liabi

Note 13 - Other Long-term Liabilities	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	( 13 Other Long-Term Liabilities Other long-term liabilities consist of the following (in thousands): September 30, December 31, 2022 2021 Accrued contingent consideration (earn-out) $ 9,079 $ 9,731 Present value of non-competition payments 9,746 8,855 Other 722 676 $ 19,547 $ 19,262

Note 14 - Income Taxes

Note 14 - Income Taxes	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	( 14 Income Taxes The determination of income tax expense in the accompanying unaudited condensed consolidated statements of income is based upon the estimated effective tax rate for the year, adjusted for the impact of any discrete items which are accounted for in the period in which they occur. The Company recorded income tax expense of approximately 22.6% and 24.9% of income before income tax expense for the three September 30, 2022 2021, nine September 30, 2022 2021,

Note 15 - Indebtedness

Note 15 - Indebtedness	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	( 15 Indebtedness On December 22, 2021, February 1, 2018. The credit facilities under the Second Amended and Restated Credit Agreement consist of a $40 million secured term loan to the Company and a secured revolving credit facility, under which the Company may December 21, 2026. March 31, 2022. may The Second Amended and Restated Credit Agreement calls for interest determined by the Bloomberg Short-Term Bank Yield Index rate (“BSBY”) plus a margin that ranges from 1.25% to 2.0% or, at the discretion of the Company, the bank’s prime rate less a margin that ranges from .25% At September 30, 2022, September 30, 2022, Long-term debt consists of the following (in thousands): September 30, 2022 Revolving credit facility $ 34,000 Term loan 37,000 Total long-term debt 71,000 Current portion (4,000 ) Long-term debt, excluding current portion $ 67,000 Future maturities of long-term debt at September 30, 2022 Term Loan Revolving credit facility Total Remainder of 2022 $ 1,000 $ - $ 1,000 2023 $ 4,000 $ - $ 4,000 2024 $ 4,000 $ - $ 4,000 2025 $ 4,000 $ - $ 4,000 2026 $ 24,000 $ 34,000 $ 58,000 $ 37,000 $ 34,000 $ 71,000 Derivative Financial Instruments The Company used interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on certain of its variable-rate debt instruments. The Company does not not The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may three The notional amount was approximately $6.4 million at September 30, 2022. September 30, 2022 December 31, 2021 three nine September 30, 2022. three nine September 30, 2021. As the Company has paid the remaining balance of the term loan that was associated with the swap in its entirety, there is no February 1, 2023.

Note 2 - Acquisitions and Div_2

Note 2 - Acquisitions and Divestiture (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Fair value of considerations transferred Cash paid at closing $ 23,608 Other liability 395 Cash from Advant (2,840 ) Total consideration $ 21,163 Purchase price allocation Accounts receivable $ 2,299 Inventory 2,410 Other current assets 213 Property, plant, and equipment 5,704 Customer contracts & relationships 2,925 Intellectual property 2,127 Non-compete agreement 259 Lease right of use assets 289 Other assets 41 Goodwill 7,140 Total identifiable assets $ 23,407 Accounts payable (772 ) Accrued expenses (668 ) Income taxes (66 ) Deferred taxes (449 ) Lease liabilities (289 ) Net assets acquired $ 21,163 Fair value of considerations transferred Cash paid at closing $ 95,000 Contingent liability (Earn-out) 5,188 Non-compete agreements 8,855 Cash from DAS (8,316 ) Working capital adjustment (115 ) Total consideration $ 100,612 Purchase price allocation Accounts receivable $ 2,351 Inventory 7,570 Other current assets 68 Property, plant, and equipment 3,314 Customer contracts & relationships 36,730 Intellectual property 2,380 Non-compete agreement 4,697 Lease right of use assets 1,221 Goodwill 51,985 Total identifiable assets $ 110,316 Accounts payable (5,238 ) Accrued expenses (3,238 ) Deferred revenue (7 ) Lease liabilities (1,221 ) Net assets acquired $ 100,612 Fair value of considerations transferred Cash paid at closing $ 9,766 Contingent liability (Earn-out) 4,543 Other liability 500 Cash from Contech (266 ) Total consideration $ 14,543 Purchase price allocation Accounts receivable $ 2,851 Inventory 2,320 Other current assets 37 Property, plant, and equipment 1,170 Customer contracts & relationships 3,043 Intellectual property 2,247 Non-compete agreement 86 Lease right of use assets 1,523 Goodwill 4,278 Total identifiable assets $ 17,555 Accounts payable (1,015 ) Accrued expenses (414 ) Deferred revenue (60 ) Lease liabilities (1,523 ) Net assets acquired $ 14,543
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2022 2021 (Unaudited) (Unaudited) (Unaudited) Sales $ 56,194 $ 266,782 $ 166,273 Operating Income $ 5,440 $ 45,268 $ 18,187 Net Income $ 4,018 $ 33,881 $ 13,796 Earnings per share: Basic $ 0.53 $ 4.48 $ 1.83 Diluted $ 0.53 $ 4.44 $ 1.82 Three-month Period Ended September 30, 2021 Nine-month Period Ended September 30, 2021 (Unaudited) (Unaudited) Sales $ 69,055 $ 201,660 Operating income $ 7,627 $ 23,030 Net income $ 5,707 $ 18,526 Earnings per share: Basic $ 0.76 $ 2.46 Diluted $ 0.75 $ 2.44

Note 3 - Revenue Recognition (T

Note 3 - Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Net sales of: 2022 2021 2022 2021 Products $ 92,860 $ 49,613 $ 251,996 $ 146,402 Tooling and Machinery 2,659 405 5,984 1,149 Engineering services 1,451 705 4,575 2,426 Total net sales $ 96,970 $ 50,723 $ 262,555 $ 149,977
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Contract Liabilities Nine Months Ended September 30, 2022 2021 Deferred revenue - beginning of period $ 4,247 $ 1,887 Increases due to consideration received from customers 4,836 2,111 Revenue recognized (4,335 ) (1,192 ) Decrease due to sale of Molded Fiber (575 ) - Deferred revenue - end of period $ 4,173 $ 2,806 Contract Assets Nine Months Ended September 30, 2022 2021 Unbilled receivables - beginning of period $ 74 $ 271 Increases due to revenue recognized, not invoiced to customers 3,065 1,461 Decreases due to customer invoicing (2,429 ) (1,509 ) Unbilled receivables - end of period $ 710 $ 223

Note 4 - Supplemental Cash Fl_2

Note 4 - Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Nine Months Ended September 30, 2022 2021 (in thousands) Cash paid for: Interest $ 1,869 $ 39 Income taxes, net of refunds 12,315 4,274 Non-cash investing and financing activities: Capital additions accrued but not yet paid $ 133 $ 225

Note 5 - Receivables and Allo_2

Note 5 - Receivables and Allowance for Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	September 30, December 31, 2022 2021 Accounts receivable–trade $ 65,814 $ 39,903 Less allowance for credit losses (741 ) (519 ) Receivables, net $ 65,073 $ 39,384
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	Allowance for Credit Losses Nine Months Ended September 30, 2022 2021 Allowance - beginning of period $ 519 $ 484 Provision for expected credit losses 275 92 Amounts written off against the allowance (53 ) (54 ) Allowance - end of period $ 741 $ 522

Note 6 - Fair Value of Financ_2

Note 6 - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	September 30, 2022 December 31, 2021 Level 2 Assets (Liabilities): Derivative financial instruments $ 26 $ (176 ) Level 3 Purchase price contingent consideration (Note 2): Accrued contingent consideration (earn-out) $ (19,079 ) $ (9,731 ) Present value of non-competition payments (9,746 ) (8,855 )

Note 7 - Share-based Compensa_2

Note 7 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs, By Award Type [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Share-based compensation related to: 2022 2021 2022 2021 Common stock grants $ 100 $ 100 $ 300 $ 300 Stock option grants 75 52 188 157 Restricted Stock Unit Awards ("RSUs") 722 498 1,882 1,314 Total share-based compensation $ 897 $ 650 $ 2,370 $ 1,771
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Under Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2021 98,671 $ 33.53 Granted 9,876 77.28 Exercised (15,245 ) 24.10 Outstanding at September 30, 2022 93,302 $ 39.70 6.13 $ 4,305 Exercisable at September 30, 2022 83,426 $ 35.26 5.71 $ 4,220 Vested and expected to vest at September 30, 2022 93,302 $ 39.70 $ 6.13 $ 4,305
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected volatility 34.7 % Expected dividends None Risk-free interest rate 2.9 % Exercise price $ 77.28 Expected term (years) 6.2 Weighted-average grant date fair value $ 30.37
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 101,168 $ 41.78 Awarded 51,981 74.94 Shares vested (49,575 ) 41.05 Shares forfeited (947 ) 64.32 Outstanding at September 30, 2022 102,627 $ 55.29

Note 8 - Inventories (Tables)

Note 8 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2022 2021 Raw materials $ 39,071 $ 22,184 Work in process 5,981 4,205 Finished goods 8,769 7,047 Total inventory $ 53,821 $ 33,436

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Lease, Cost [Table Text Block]	Nine Months Ended September 30, ($ in thousands) 2022 2021 Lease Cost: Finance lease cost: Amortization of right of use assets $ 45 $ 12 Interest on lease liabilities 4 2 Operating lease cost 1,962 896 Variable lease cost 228 169 Short-term lease cost 49 30 Total lease cost $ 2,288 $ 1,109 Nine Months Ended September 30, ($ in thousands) 2022 2021 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 1,839 $ 909 Financing cash flows from finance leases 47 11 Weighted-average remaining lease term (years): Finance 3.79 5.58 Operating 3.88 1.39 Weighted-average discount rate: Finance 2.10 % 2.26 % Operating 2.75 % 3.95 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Finance Operating Remainder of 2022 $ 16 $ 611 2023 63 2,211 2024 63 2,190 2025 63 1,957 2026 28 1,733 Thereafter 6 4,775 Total lease payments 239 13,477 Less: Interest (9 ) (1,198 ) Present value of lease liabilities $ 230 $ 12,279

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic weighted average common shares outstanding 7,570 7,531 7,559 7,522 Weighted average common equivalent shares due to restricted stock, stock options and RSUs 68 66 70 63 Diluted weighted average common shares outstanding 7,638 7,597 7,629 7,585

Note 11 - Segment Reporting (Ta

Note 11 - Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021(1) 2022 2021(1) Market Net Sales % Net Sales % Net Sales % Net Sales % Medical $ 81,591 84.1 % $ 32,376 63.8 % $ 208,464 79.4 % $ 95,088 63.4 % Automotive 4,681 4.8 % 3,852 7.6 % 13,383 5.1 % 12,065 8.0 % Aerospace & Defense 3,590 3.7 % 3,881 7.7 % 11,097 4.2 % 12,636 8.4 % Consumer 3,099 3.2 % 6,449 12.7 % 15,644 6.0 % 18,125 12.1 % Industrial 2,748 2.8 % 2,162 4.3 % 7,924 2.9 % 6,508 4.2 % Electronics 1,261 1.3 % 2,003 4.0 % 6,043 2.4 % 5,555 3.7 % Net Sales $ 96,970 100.0 % $ 50,723 100.0 % $ 262,555 100.0 % $ 149,977 100.0 %

Note 12 - Goodwill and Other _2

Note 12 - Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Goodwill [Table Text Block]	Goodwill December 31, 2021 $ 107,905 Acquired in Advant Medical business combination (See Note 2) 7,140 DAS working capital adjustment 196 Sale of Molded Fiber (1,778 ) Foreign currency translation (806 ) September 30, 2022 $ 112,657
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intellectual Property / Tradename & Brand Non- Compete Customer List Total Weighted-average amortization period (years) 11.9 9.3 20 Gross amount $ 6,881 $ 5,474 $ 64,922 $ 77,277 Accumulated amortization (570 ) (822 ) (6,844 ) (8,236 ) Net balance $ 6,311 $ 4,652 $ 58,078 $ 69,041
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Remainder of 2022 $ 1,123 2023 4,409 2024 4,401 2025 4,401 2026 4,398 Thereafter 50,309 Total $ 69,041

Note 13 - Other Long-term Lia_2

Note 13 - Other Long-term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Other Noncurrent Liabilities [Table Text Block]	September 30, December 31, 2022 2021 Accrued contingent consideration (earn-out) $ 9,079 $ 9,731 Present value of non-competition payments 9,746 8,855 Other 722 676 $ 19,547 $ 19,262

Note 15 - Indebtedness (Tables)

Note 15 - Indebtedness (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2022 Revolving credit facility $ 34,000 Term loan 37,000 Total long-term debt 71,000 Current portion (4,000 ) Long-term debt, excluding current portion $ 67,000
Schedule of Maturities of Long-Term Debt [Table Text Block]	Term Loan Revolving credit facility Total Remainder of 2022 $ 1,000 $ - $ 1,000 2023 $ 4,000 $ - $ 4,000 2024 $ 4,000 $ - $ 4,000 2025 $ 4,000 $ - $ 4,000 2026 $ 24,000 $ 34,000 $ 58,000 $ 37,000 $ 34,000 $ 71,000

Note 2 - Acquisitions and Div_3

Note 2 - Acquisitions and Divestiture (Details Textual) € in Thousands, $ in Thousands							3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended	21 Months Ended
	Mar. 17, 2022 USD ($)	Mar. 16, 2022 USD ($)	Mar. 16, 2022 EUR (€)	Dec. 22, 2021 USD ($)	Dec. 21, 2021 USD ($)	Oct. 12, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 EUR (€)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Jul. 26, 2022 USD ($)
Gain (Loss) on Disposition of Business							$ 15,623			$ 15,623
Business Combination, Acquisition Related Costs							10	$ 154		1,027	154
Advant Medical [Member]
Business Acquisition, Percentage of Voting Interests Acquired		100%	100%
Payments to Acquire Businesses, Net of Cash Acquired, Total			€ 19,000							20,768	0
Payments to Acquire Businesses, Gross	$ 23,608	$ 21,200
Business Combination, Acquisition Related Costs										759		$ 30	$ 789
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual										13,600
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual										1,800
DAS Medical [Member]
Business Acquisition, Percentage of Voting Interests Acquired				100%
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 66,700						(115)	$ 0
Payments to Acquire Businesses, Gross					$ 95,000
Business Combination, Acquisition Related Costs										155		293	448
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				20,000
Business Combination, Working Capital Adjustment				(115,000)	$ 115
DAS Medical [Member] | Goodwill Agreement [Member]
Payments to Acquire Businesses, Gross				20,000
DAS Medical [Member] | Non-Competition Agreements [Member]
Payments to Acquire Businesses, Gross				$ 10,000					€ 375
Business Combination, Agreement Term (Year)				10 years					5 years
Contech Medical, Inc [Member]
Business Acquisition, Percentage of Voting Interests Acquired						100%
Payments to Acquire Businesses, Net of Cash Acquired, Total						$ 9,500
Payments to Acquire Businesses, Gross						9,766
Business Combination, Acquisition Related Costs										113		$ 40	153
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						5,000
Business Combination, Contingent Consideration, Liability, Total						$ 500
molded fiber business (“MFT”) and related real estate in Iowa [Member]
Disposal Group, Including Discontinued Operation, Consideration														$ 31,400
Disposal Group, Including Discontinued Operation, Assets, Noncurrent, Total							15,400			15,400			$ 15,400
Gain (Loss) on Disposition of Business							$ 15,600			15,600
Disposal Group, Including Discontinued Operation, Consideration, Held in Escrow														2,600
Disposal Group, Including Discontinued Operation, Revenue										$ 21,300
molded fiber business (“MFT”) and related real estate in Iowa [Member] | Scenario, Adjustment [Member]
Disposal Group, Including Discontinued Operation, Consideration														$ 200

Note 2 - Acquisitions - Assets

Note 2 - Acquisitions - Assets Acquires and Liabilities Assumed (Details) - USD ($) $ in Thousands	Mar. 17, 2022	Mar. 16, 2022	Dec. 22, 2021	Dec. 21, 2021	Oct. 12, 2021	Sep. 30, 2022	Dec. 31, 2021
Goodwill						$ 112,657	$ 107,905
Advant Medical [Member]
Cash paid at closing	$ 23,608	$ 21,200
Other liability	395
Cash from Advant	(2,840)
Total consideration	21,163
Accounts receivable	2,299
Inventory	2,410
Other current assets	213
Property, plant, and equipment	5,704
Lease right of use assets	289
Other assets	41
Goodwill	7,140
Total identifiable assets	23,407
Accounts payable	(772)
Accrued expenses	(668)
Income taxes	(66)
Deferred taxes	(449)
Lease liabilities	(289)
Net assets acquired	21,163
Advant Medical [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships	2,925
Advant Medical [Member] | Intellectual Property [Member]
Customer contracts & relationships	2,127
Advant Medical [Member] | Noncompete Agreements [Member]
Customer contracts & relationships	$ 259
DAS Medical [Member]
Cash paid at closing				$ 95,000
Cash from Advant				(8,316)
Total consideration				100,612
Accounts receivable				2,351
Inventory				7,570
Other current assets				68
Property, plant, and equipment				3,314
Lease right of use assets				1,221
Goodwill				51,985
Total identifiable assets				110,316
Accounts payable				(5,238)
Accrued expenses				(3,238)
Lease liabilities				(1,221)
Net assets acquired				100,612
Contingent liability (Earn-out)				5,188
Non-compete agreements				8,855
Working capital adjustment			$ 115,000	(115)
Deferred revenue				(7)
DAS Medical [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships				36,730
DAS Medical [Member] | Intellectual Property [Member]
Customer contracts & relationships				2,380
DAS Medical [Member] | Noncompete Agreements [Member]
Customer contracts & relationships				$ 4,697
Contech Medical, Inc [Member]
Cash paid at closing					$ 9,766
Other liability					500
Cash from Advant					(266)
Total consideration					14,543
Accounts receivable					2,851
Inventory					2,320
Other current assets					37
Property, plant, and equipment					1,170
Lease right of use assets					1,523
Goodwill					4,278
Total identifiable assets					17,555
Accounts payable					(1,015)
Accrued expenses					(414)
Lease liabilities					(1,523)
Net assets acquired					14,543
Contingent liability (Earn-out)					4,543
Deferred revenue					(60)
Contech Medical, Inc [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships					3,043
Contech Medical, Inc [Member] | Intellectual Property [Member]
Customer contracts & relationships					2,247
Contech Medical, Inc [Member] | Noncompete Agreements [Member]
Customer contracts & relationships					$ 86

Note 2 - Acquisition - Pro Form

Note 2 - Acquisition - Pro Forma Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Advant Medical [Member]
Sales	$ 56,194		$ 266,782	$ 166,273
Operating Income	5,440		45,268	18,187
Net Income	$ 4,018		$ 33,881	$ 13,796
Basic (in dollars per share)	$ 0.53		$ 4.48	$ 1.83
Diluted (in dollars per share)	$ 0.53		$ 4.44	$ 1.82
Contech Medical, Inc and DAS Medical [Member]
Sales		$ 69,055		$ 201,660
Operating Income		7,627		23,030
Net Income		$ 5,707		$ 18,526
Basic (in dollars per share)		$ 0.76		$ 2.46
Diluted (in dollars per share)		$ 0.75		$ 2.44

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Deferred Revenue [Member]
Contract with Customer, Liability, Revenue Recognized	$ 2,200	$ 659

Note 3 - Revenue Recognition -

Note 3 - Revenue Recognition - Revenue Disaggregated by the Major Types of Goods and Services Sold (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net sales	$ 96,970	$ 50,723	$ 262,555	$ 149,977
Product [Member]
Net sales	92,860	49,613	251,996	146,402
Tooling and Machinery [Member]
Net sales	2,659	405	5,984	1,149
Engineering and Development [Member]
Net sales	$ 1,451	$ 705	$ 4,575	$ 2,426

Note 3 - Revenue Recognition _2

Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Deferred revenue	$ 4,247	$ 1,887
Increases due to consideration received from customers	4,836	2,111
Revenue recognized	(4,335)	(1,192)
Decrease due to sale of Molded Fiber	(575)	0
Deferred revenue	4,173	2,806
Unbilled receivables - beginning of period	74	271
Increases due to revenue recognized, not invoiced to customers	3,065	1,461
Decreases due to customer invoicing	(2,429)	(1,509)
Unbilled receivables - end of period	$ 710	$ 223

Note 4 - Supplemental Cash Fl_3

Note 4 - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash paid for:
Interest	$ 1,869	$ 39
Income taxes, net of refunds	12,315	4,274
Non-cash investing and financing activities:
Capital additions accrued but not yet paid	$ 133	$ 225

Note 5 - Receivables and Allo_3

Note 5 - Receivables and Allowance for Credit Losses - Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts receivable–trade	$ 65,814	$ 39,903
Less allowance for credit losses	(741)	(519)
Receivables, net	$ 65,073	$ 39,384

Note 5 - Receivables and Allo_4

Note 5 - Receivables and Allowance for Credit Losses - Summary of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Allowance - beginning of period	$ 519	$ 484
Provision for expected credit losses	275	92
Amounts written off against the allowance	(53)	(54)
Allowance - end of period	$ 741	$ 522

Note 6 - Fair Value of Financ_3

Note 6 - Fair Value of Financial Instruments (Details Textual) € in Thousands, $ in Thousands			1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Dec. 22, 2021 USD ($)	Dec. 21, 2021 USD ($)	Nov. 09, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 EUR (€)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ (3,346)	$ 0		$ (9,348)	$ 0
Contech Medical, Inc and DAS Medical [Member]
Business Combination, Consideration Transferred, Liabilities Incurred							25,000
Business Combination, Contingent Consideration, Liability, Total				19,100			19,100		$ 9,700
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ 3,300			$ 9,300
Contech Medical, Inc and DAS Medical [Member] | Subsequent Event [Member]
Payment for Contingent Consideration Liability, Financing Activities			$ 5,000,000,000
DAS Medical [Member]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 5,188
Payments to Acquire Businesses, Gross		$ 95,000
DAS Medical [Member] | Non-Competition Agreements [Member]
Payments to Acquire Businesses, Gross	$ 10,000					€ 375
Business Combination, Agreement Term (Year)	10 years					5 years
Business Combination, Agreement Term, Final Three Years (Year)						3 years

Note 6 - Fair Value of Financ_4

Note 6 - Fair Value of Financial Instruments - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 2 [Member]
Derivative financial instruments	$ 26	$ (176)
Fair Value, Inputs, Level 3 [Member]
Accrued contingent consideration (earn-out)	19,079	9,731
Present value of non-competition payments	$ 9,746	$ 8,855

Note 7 - Share-based Compensa_3

Note 7 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 08, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Price (in dollars per share)	$ 77.28
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 4,400			$ 4,400
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					2 years 6 months
Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	9,876
Share-Based Payment Arrangement [Member]
Share-Based Payment Arrangement, Expense, Tax Benefit		$ 485	$ 167		$ 1,100	$ 608
Employee and Nonemployee Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					9,876
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value					$ 1,100	164
Proceeds from Stock Options Exercised					$ 367	$ 162
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)				0	1,876
Shares Paid For Tax Withholding For Share Based Compensation, Average Market Price (in dollars per share)					$ 95.82
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)					19,425	14,112
Shares Paid for Tax Withholding for Share Based Compensation Market Price (in dollars per share)					$ 67.05	$ 52.47

Note 7 - Share-based Compensa_4

Note 7 - Share-based Compensation - Compensation Cost (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based compensation	$ 897	$ 650	$ 2,370	$ 1,771
Common Stock [Member]
Share-based compensation	100	100	300	300
Employee and Nonemployee Stock Option [Member]
Share-based compensation	75	52	188	157
Restricted Stock Units (RSUs) [Member]
Share-based compensation	$ 722	$ 498	$ 1,882	$ 1,314

Note 7 - Share-based Compensa_5

Note 7 - Share-based Compensation - Summary of Stock Option Activity (Details) - Employee and Nonemployee Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022
Outstanding, shares under options (in shares)	98,671
Outstanding, weighted average exercise price (in dollars per share)	$ 33.53
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	9,876
Granted (in dollars per share)	$ 77.28
Exercised, shares under options (in shares)	(15,245)
Granted, weighted average exercise price (in dollars per share)	$ 24.10
Outstanding, shares under options (in shares)	93,302
Outstanding, weighted average exercise price (in dollars per share)	$ 39.70
Outstanding, weighted average remaining contractual life (Year)	6 years 1 month 17 days
Outstanding, aggregate intrinsic value	$ 4,305
Exercisable, shares under options (in shares)	83,426
Exercisable, weighted average exercise price (in dollars per share)	$ 35.26
Exercisable, weighted average remaining contractual life (Year)	5 years 8 months 15 days
Exercisable, aggregate intrinsic value	$ 4,220
Vested and expected to vest, shares under options (in shares)	93,302
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 39.70
Vested and expected to vest, weighted average remaining contractual life (Year)	6 years 1 month 17 days
Vested and expected to vest, aggregate intrinsic value	$ 4,305

Note 7 - Share-based Compensa_6

Note 7 - Share-based Compensation - Black-Scholes Option Pricing Model (Details)	Jun. 08, 2022 $ / shares
Expected volatility	34.70%
Expected dividends	0%
Risk-free interest rate	2.90%
Exercise price (in dollars per share)	$ 77.28
Expected term (years) (Year)	6 years 2 months 12 days
Weighted-average grant date fair value (in dollars per share)	$ 30.37

Note 7 - Share-based Compensa_7

Note 7 - Share-based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Outstanding, restricted stock units (in shares) | shares	101,168
Outstanding, weighted average award date fair value (in dollars per share) | $ / shares	$ 41.78
Awarded, restricted stock units (in shares) | shares	51,981
Awarded, weighted average award date fair value (in dollars per share) | $ / shares	$ 74.94
Shares vested, restricted stock units (in shares) | shares	(49,575)
Shares vested, weighted average award date fair value (in dollars per share) | $ / shares	$ 41.05
Shares forfeited (in shares) | shares	(947)
Shares forfeited (in dollars per share) | $ / shares	$ 64.32
Outstanding, restricted stock units (in shares) | shares	102,627
Outstanding, weighted average award date fair value (in dollars per share) | $ / shares	$ 55.29

Note 8 - Inventories - Summary

Note 8 - Inventories - Summary of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Raw materials	$ 39,071	$ 22,184
Work in process	5,981	4,205
Finished goods	8,769	7,047
Total inventory	$ 53,821	$ 33,436

Note 9 - Leases - Lease Cost (D

Note 9 - Leases - Lease Cost (Details) - USD ($) $ in Thousands	6 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lease Cost:
Amortization of right of use assets			$ 45	$ 12
Interest on lease liabilities			4	2
Operating lease cost			1,962	896
Variable lease cost			228	169
Short-term lease cost			49	30
Total lease cost			2,288	1,109
Operating cash flows from operating leases	$ 1,839	$ 909
Financing cash flows from finance leases	$ 47	$ 11	$ 47	$ 13
Finance (Year)	3 years 9 months 14 days	5 years 6 months 29 days
Operating (Year)	3 years 10 months 17 days	1 year 4 months 20 days
Finance	2.10%	2.26%
Operating	2.75%	3.95%

Note 9 - Leases - Aggregate Fut

Note 9 - Leases - Aggregate Future Lease Payments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Remainder of 2022. finance	$ 16
Remainder of 2022, operating	611
2023, finance	63
2023, operating	2,211
2024, finance	63
2024, operating	2,190
2025, finance	63
2025, operating	1,957
2026, finance	28
2026, operating	1,733
Thereafter, finance	6
Thereafter, operating	4,775
Total lease payments, finance	239
Total lease payments, operating	13,477
Less: Interest, finance	(9)
Less: Interest, operating	(1,198)
Present value of lease liabilities, finance	230
Present value of lease liabilities, operating	$ 12,279

Note 10 - Net Income Per Shar_2

Note 10 - Net Income Per Share (Details Textual) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	9,876	10,716	9,876	10,716

Note 10 - Net Income Per Shar_3

Note 10 - Net Income Per Share - Weighted Average Number of Shares Used to Compute Net EPS (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Basic weighted average common shares outstanding (in shares)	7,570	7,531	7,559	7,522
Weighted average common equivalent shares due to restricted stock, stock options and RSUs (in shares)	68	66	70	63
Diluted weighted average common shares outstanding (in shares)	7,638	7,597	7,629	7,585

Note 11 - Segment Reporting (De

Note 11 - Segment Reporting (Details Textual) - Customer Concentration Risk [Member] - One Customer [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Revenue Benchmark [Member]
Concentration Risk, Percentage	25.10%	20.50%
Accounts Receivable [Member]
Concentration Risk, Percentage		10.70%

Note 11 - Segment Reporting - N

Note 11 - Segment Reporting - Net Sales by Market (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net sales		$ 96,970	$ 50,723	$ 262,555	$ 149,977
Percentage of concentration risk	[1]	100%	100%	100%	100%
Medical [Member]
Net sales		$ 81,591	$ 32,376	$ 208,464	$ 95,088
Percentage of concentration risk	[1]	84.10%	63.80%	79.40%	63.40%
Automotive [Member]
Net sales		$ 4,681	$ 3,852	$ 13,383	$ 12,065
Percentage of concentration risk	[1]	4.80%	7.60%	5.10%	8%
Aerospace & Defense [Member]
Net sales		$ 3,590	$ 3,881	$ 11,097	$ 12,636
Percentage of concentration risk	[1]	3.70%	7.70%	4.20%	8.40%
Consumer [Member]
Net sales		$ 3,099	$ 6,449	$ 15,644	$ 18,125
Percentage of concentration risk	[1]	3.20%	12.70%	6%	12.10%
Industrial [Member]
Net sales		$ 2,748	$ 2,162	$ 7,924	$ 6,508
Percentage of concentration risk	[1]	2.80%	4.30%	2.90%	4.20%
Electronics [Member]
Net sales		$ 1,261	$ 2,003	$ 6,043	$ 5,555
Percentage of concentration risk	[1]	1.30%	4%	2.40%	3.70%
[1]Certain amounts for the three and nine months ended September 30, 2021, were reclassified between markets to conform to the current period presentation.

Note 12 - Goodwill and Other _3

Note 12 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Amortization of Intangible Assets	$ 1,100	$ 314	$ 3,300	$ 943

Note 12 - Goodwill and Other _4

Note 12 - Goodwill and Other Intangible Assets - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Balance	$ 107,905
Acquired in Advant Medical business combination (See Note 2)	7,140
DAS working capital adjustment	196
Sale of Molded Fiber	(1,778)
Foreign currency translation	(806)
Balance	$ 112,657

Note 12 - Goodwill and Other _5

Note 12 - Goodwill and Other Intangible Assets - Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Gross amount	$ 77,277
Accumulated amortization	(8,236)
Net balance	$ 69,041	$ 67,585
Intellectual Property/ Tradename and Brand [Member]
Weighted-average amortization period (years) (Year)	11 years 10 months 24 days
Gross amount	$ 6,881
Accumulated amortization	(570)
Net balance	$ 6,311
Noncompete Agreements [Member]
Weighted-average amortization period (years) (Year)	9 years 3 months 18 days
Gross amount	$ 5,474
Accumulated amortization	(822)
Net balance	$ 4,652
Customer Lists [Member]
Weighted-average amortization period (years) (Year)	20 years
Gross amount	$ 64,922
Accumulated amortization	(6,844)
Net balance	$ 58,078

Note 12 - Goodwill and Other _6

Note 12 - Goodwill and Other Intangible Assets - Future Amortization of Intangible Assets (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Remainder of 2022	$ 1,123
2023	4,409
2024	4,401
2025	4,401
2026	4,398
Thereafter	50,309
Total	$ 69,041

Note 13 - Other Long-term Lia_3

Note 13 - Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued contingent consideration (earn-out)	$ 9,079	$ 9,731
Present value of non-competition payments	9,746	8,855
Other	722	676
Other Liabilities, Noncurrent	$ 19,547	$ 19,262

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Effective Income Tax Rate Reconciliation, Percent, Total	22.60%	24.90%	22.40%	23.60%

Note 15 - Indebtedness (Details

Note 15 - Indebtedness (Details Textual) - USD ($)			3 Months Ended		9 Months Ended
	Dec. 22, 2021	Feb. 01, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
Long-Term Debt, Total			$ 71,000,000		$ 71,000,000
Interest Rate Swap [Member]
Derivative, Notional Amount		$ 20,000,000	6,400,000		6,400,000
Derivative, Term of Contract (Year)		5 years
Derivative, Fixed Interest Rate		2.70%
Interest Rate Swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivative, Gain (Loss) on Derivative, Net, Total			20,000	$ 2,000	202,000	$ 4,000
Interest Rate Swap [Member] | Other Assets [Member]
Derivative, Fair Value, Net, Total			26,000		26,000
Interest Rate Swap [Member] | Other Current Liabilities [Member]
Derivative, Fair Value, Net, Total							$ (176,000)
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member]
Debt Instrument, Face Amount	$ 130,000,000
Long-Term Debt, Total			71,000,000		71,000,000
Letters of Credit Outstanding, Amount			$ 700,000		$ 700,000
Debt Instrument, Interest Rate, Stated Percentage			4.60%		4.60%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Bloomberg Short-term Bank Yield Index Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.25%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Bloomberg Short-term Bank Yield Index Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Secured Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 90,000,000
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Secured Term Loan [Member]
Debt Instrument, Face Amount	40,000,000
Debt Instrument, Periodic Payment, Principal	$ 1,000,000

Note 15 - Indebtedness - Long-t

Note 15 - Indebtedness - Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Total long-term debt	$ 71
Current portion	(4)	$ (4)
Long-term debt, excluding current portion	67	$ 71
Term Loan [Member]
Total long-term debt	37
Revolving Credit Facility [Member] | Line of Credit [Member]
Total long-term debt	$ 34

Note 15 - Indebtedness - Future

Note 15 - Indebtedness - Future Maturities of Long-term Debt (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Remainder of 2022	$ 1,000
2023	4,000
2024	4,000
2025	4,000
2026	58,000
Long-Term Debt, Total	71,000
Line of Credit [Member] | Revolving Credit Facility [Member]
Remainder of 2022	0
2023	0
2024	0
2025	0
2026	34,000
Long-Term Debt, Total	34,000
Term Loan [Member]
Remainder of 2022	1,000
2023	4,000
2024	4,000
2025	4,000
2026	24,000
Long-Term Debt, Total	$ 37,000